Publication | Open Access

Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial

Disease ProgressionImmunologyClinical TrialsClinical NeurologyNeurological ProgressNeurologyMultiple SclerosisImmunotherapyMedicineNeuroimmunologyInterferon Beta-1bBenefit Trial